keyword
Keywords Pulmonary drug delivery animal...

Pulmonary drug delivery animal model

https://read.qxmd.com/read/38673985/an-overview-of-frog-skin-derived-esc-peptides-promising-multifunctional-weapons-against-pseudomonas-aeruginosa-induced-pulmonary-and-ocular-surface-infections
#1
REVIEW
Maria Luisa Mangoni, Maria Rosa Loffredo, Bruno Casciaro, Loretta Ferrera, Floriana Cappiello
Antimicrobial resistance is a silent pandemic harming human health, and Pseudomonas aeruginosa is the most common bacterium responsible for chronic pulmonary and eye infections. Antimicrobial peptides (AMPs) represent promising alternatives to conventional antibiotics. In this review, the in vitro/in vivo activities of the frog skin-derived AMP Esc(1-21) are shown. Esc(1-21) rapidly kills both the planktonic and sessile forms of P. aeruginosa and stimulates migration of epithelial cells, likely favoring repair of damaged tissue...
April 16, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38651940/a-mouse-model-of-progressive-lung-fibrosis-with-cutaneous-involvement-induced-by-a-combination-of-oropharyngeal-and-osmotic-minipump-bleomycin-delivery
#2
JOURNAL ARTICLE
Andrea Grandi, Erica Ferrini, Matteo Zoboli, Davide Buseghin, Francesca Pennati, Zahra Khalajzeyqami, Roberta Ciccimarra, Gino Villetti, Franco Fabio Stellari
Systemic sclerosis (SSc) with interstitial lung disease (SSc-ILD) lacks curative pharmacological treatments, thus necessitating effective animal models for candidate drug discovery. Existing Bleomycin (BLM)-induced SSc-ILD mouse models feature spatially limited pulmonary fibrosis, spontaneously resolving after 28 days. Here, we present an alternative BLM administration approach in female C57BL/6 mice, combining oropharyngeal aspiration (OA) and subcutaneous mini-pump delivery (pump) of BLM to induce a sustained and more persistent fibrosis, while retaining stable skin fibrosis...
April 23, 2024: American Journal of Physiology. Lung Cellular and Molecular Physiology
https://read.qxmd.com/read/38247549/expression-of-inflammatory-genes-in-murine-lungs-in-a-model-of-experimental-pulmonary-hypertension-effects-of-an-antibody-based-targeted-delivery-of-interleukin-9
#3
JOURNAL ARTICLE
Judith Heiss, Katja Grün, Isabell Singerer, Laura Tempel, Mattia Matasci, Christian Jung, Alexander Pfeil, P Christian Schulze, Dario Neri, Marcus Franz
BACKGROUND: Pathogenesis of pulmonary hypertension (PH) is a multifactorial process driven by inflammation and pulmonary vascular remodeling. To target these two aspects of PH, we recently tested a novel treatment: Interleukin-9 (IL9) fused to F8, an antibody that binds to the extra-domain A of fibronectin (EDA+ Fn). As EDA+ Fn is not found in healthy adult tissue but is expressed during PH, IL9 is delivered specifically to the tissue affected by PH. We found that F8IL9 reduced pulmonary vascular remodeling and attenuated PH compared with sham-treated mice...
January 3, 2024: Advances in Respiratory Medicine
https://read.qxmd.com/read/38244667/multitask-learning-for-predicting-pulmonary-absorption-of-chemicals
#4
JOURNAL ARTICLE
Yu-Wen Chiu, Chun-Wei Tung, Chia-Chi Wang
Pulmonary is an important route for drug delivery and chemical exposure. To streamline the chemical assessment process for the reduction of animal experiments, several animal-free models were developed for pulmonary absorption research. While Calu-3 and Caco-2 cells and their derived computational models were used in estimating pulmonary permeability, the ex vivo isolated perfused lung (IPL) models are considered more clinically relevant measurements. However, the IPL experiments are resource-consuming making it infeasible for the large-scale screening of potential inhaled toxicants and drugs...
January 18, 2024: Food and Chemical Toxicology
https://read.qxmd.com/read/38183140/translational-medicine-for-acute-lung-injury
#5
REVIEW
Jianguo Zhang, Yumeng Guo, Michael Mak, Zhimin Tao
Acute lung injury (ALI) is a complex disease with numerous causes. This review begins with a discussion of disease development from direct or indirect pulmonary insults, as well as varied pathogenesis. The heterogeneous nature of ALI is then elaborated upon, including its epidemiology, clinical manifestations, potential biomarkers, and genetic contributions. Although no medication is currently approved for this devastating illness, supportive care and pharmacological intervention for ALI treatment are summarized, followed by an assessment of the pathophysiological gap between human ALI and animal models...
January 5, 2024: Journal of Translational Medicine
https://read.qxmd.com/read/38171710/lung-to-heart-nano-in-micro-peptide-promotes-cardiac-recovery-in-a-pig-model-of-chronic-heart%C3%A2-failure
#6
JOURNAL ARTICLE
Alessio Alogna, Leonhard Berboth, Alessandro Faragli, Jens Ötvös, Francesco Paolo Lo Muzio, Vittoria di Mauro, Jessica Modica, Eride Quarta, Lukas Semmler, Peter Maximilian Deißler, Yannic Wanja Berger, Khai Liem Tran, Beatrice de Marchi, Gianluigi Longinotti-Buitoni, Lorenzo Degli Esposti, Etienne Guillot, Didier Bazile, Michele Iafisco, Alessandro Dotti, Marie-Louise Bang, Claudio de Luca, Christina Brandenberger, Louise Benazzi, Dario di Silvestre, Antonella de Palma, Uwe Primeßnig, Felix Hohendanner, Simone Perna, Francesca Buttini, Paolo Colombo, Christian Mühlfeld, Paul Steendijk, Pierluigi Mauri, Carsten Tschöpe, Barry Borlaug, Burkert M Pieske, Philipp Attanasio, Heiner Post, Frank R Heinzel, Daniele Catalucci
BACKGROUND: The lack of disease-modifying drugs is one of the major unmet needs in patients with heart failure (HF). Peptides are highly selective molecules with the potential to act directly on cardiomyocytes. However, a strategy for effective delivery of therapeutics to the heart is lacking. OBJECTIVES: In this study, the authors sought to assess tolerability and efficacy of an inhalable lung-to-heart nano-in-micro technology (LungToHeartNIM) for cardiac-specific targeting of a mimetic peptide (MP), a first-in-class for modulating impaired L-type calcium channel (LTCC) trafficking, in a clinically relevant porcine model of HF...
January 2, 2024: Journal of the American College of Cardiology
https://read.qxmd.com/read/38136765/colistin-effects-on-emphysematous-lung-in-an-lps-sepsis-model
#7
JOURNAL ARTICLE
Rodopi Stamatiou, Anna Vasilaki, Dimitra Tzini, Konstantina Deskata, Konstantina Zacharouli, Maria Ioannou, Markos Sgantzos, Epaminondas Zakynthinos, Demosthenes Makris
Emphysema is prevalent in various respiratory diseases like Chronic Obstructive Pulmonary Disease (COPD) and cystic fibrosis. Colistin and vasoconstrictive drugs are crucial for treating these patients when diagnosed with sepsis in the ICU. This study examines colistin impact in ether-induced emphysematous septic and non-septic animals, focusing on lung pathophysiology and inflammatory responses, including IL-1β, TNF-α, AMPK, caspase-3, cyclin-D1, and colistin levels in lung tissue. All animals exhibited significant emphysematous changes, accentuated by LPS-induced septic conditions, validating the emphysema model and highlighting the exacerbating effect of sepsis on lung pathology...
December 14, 2023: Antibiotics
https://read.qxmd.com/read/38092320/intranasal-administration-of-sertraline-ensures-sustained-brain-delivery-and-antidepressant-effect-in-a-mouse-model-of-depression
#8
JOURNAL ARTICLE
Soraia Silva, Carla Fonseca, Joana Bicker, Amílcar Falcão, Ana Fortuna
The pursuit of more potent and efficacious antidepressant therapies is of utmost significance. Herein, intranasal (IN) route was investigated for sertraline brain delivery, encompassing a comparative pharmacokinetic study after a single-dose administration to mice by IN, intravenous (IV) (4.87 mg/kg) and oral (10 mg/kg) routes, and an efficacy/toxicity study to explore the therapeutic effect in mice subjected to the unpredictable chronic mild stress (UCMS) protocol. Neurotransmitters and melatonin were quantified in prefrontal cortex and plasma, respectively...
December 11, 2023: European Journal of Pharmaceutics and Biopharmaceutics
https://read.qxmd.com/read/37826939/superoxide-dismutase-secreting-bacillus-amyloliquefaciens-spores-attenuate-pulmonary-fibrosis
#9
JOURNAL ARTICLE
Na Hyun Kim, Hee Young Kim, Jang Ho Lee, Inik Chang, Sun-Hee Heo, Jiseon Kim, Jeong Hyun Kim, Jung-Hyun Kang, Sei Won Lee
Superoxide dismutase (SOD) can convert active oxygen to oxygen or hydrogen peroxide, and recent research has suggested that it can protect against lung damage and fibrosis. Clinical applications based on SOD remain limited however due to costs and low stability. We here investigated a potential new therapeutic delivery system for this enzyme in the form of SOD-overexpressing Bacillus amyloliquefaciens spores which we introduced into a bleomycin-induced pulmonary fibrosis mouse model. This treatment significantly alleviated the disease, as quantified using a hydroxyproline assay, at 107 colony forming unit (CFU) of Bacillus spores per day...
October 9, 2023: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/37631023/mannose-functionalized-isoniazid-loaded-nanostructured-lipid-carriers-for-pulmonary-delivery-in-vitro-prospects-and-in-vivo-therapeutic-efficacy-assessment
#10
JOURNAL ARTICLE
Shaveta Ahalwat, Dinesh Chandra Bhatt, Surbhi Rohilla, Vikas Jogpal, Kirti Sharma, Tarun Virmani, Girish Kumar, Abdulsalam Alhalmi, Ali S Alqahtani, Omar M Noman, Marwan Almoiliqy
Resistance to isoniazid (INH) is common and increases the possibility of acquiring multidrug-resistant tuberculosis. For this study, isoniazid-loaded nanostructured lipid carriers (INH-NLCs) were developed and effectively functionalized with mannose (Man) to enhance the residence time of the drug within the lungs via specific delivery and increase the therapeutic efficacy of the formulation. The mannose-functionalized isoniazid-loaded nanostructured lipid carrier (Man-INH-NLC) formulation was evaluated with respect to various formulation parameters, namely, encapsulation efficiency (EE), drug loading (DL), average particle size (PS), zeta potential (ZP), polydispersity index (PDI), in vitro drug release (DR), and release kinetics...
August 4, 2023: Pharmaceuticals
https://read.qxmd.com/read/37607097/disposable-dosators-intended-for-dry-powder-delivery-to-mice
#11
JOURNAL ARTICLE
Sara E Maloney, Ian E Stewart, Jeffrey B Mecham, Mercedes Gonzalez-Juarrero, Bernd Meibohm, Anthony J Hickey
Dry powder inhalers offer numerous advantages for delivering drugs to the lungs, including stable solid-state drug formulations, device portability, bolus metering and dosing, and a propellant-free dispersal mechanism. To develop pharmaceutical dry powder aerosol products, robust in vivo testing is essential. Typically, initial studies involve using a murine model for preliminary evaluation before conducting formal studies in larger animal species. However, a significant limitation in this approach is the lack of suitable device technology to accurately and reproducibly deliver dry powders to small animals, hindering such models' utility...
August 18, 2023: Journal of Visualized Experiments: JoVE
https://read.qxmd.com/read/37541763/-mesna-improves-outcomes-of-sulfur-mustard-inhalation-toxicity-in-an-acute-rat-model
#12
JOURNAL ARTICLE
Heidi J Nick, Carly A Johnson, Amber R Stewart, Sarah E Christeson, Leslie A Bloomquist, Amanda S Appel, Abigail B Donkor, Livia A Veress, Brian A Logue, Preston E Bratcher, Carl W White
Inhalation of high levels of sulfur mustard (SM), a potent vesicating and alkylating agent used in chemical warfare, results in acutely lethal pulmonary damage. Sodium 2-mercaptoethane sulfonate (mesna) is an organosulfur compound that is currently FDA-approved for decreasing the toxicity of mustard-derived chemotherapeutic alkylating agents like ifosfamide and cyclophosphamide. The nucleophilic thiol of mesna is a suitable reactant for the neutralization of the electrophilic group of toxic mustard intermediates...
August 4, 2023: Journal of Pharmacology and Experimental Therapeutics
https://read.qxmd.com/read/37538179/recent-advances-in-nanoparticle-applications-in-respiratory-disorders-a-review
#13
REVIEW
Mohammad Ehsan Taghavizadeh Yazdi, Mohsen Qayoomian, Sima Beigoli, Mohammad Hossein Boskabady
Various nanoparticles are used in the discovery of new nanomedicine to overcome the shortages of conventional drugs. Therefore, this article presents a comprehensive and up-to-date review of the effects of nanoparticle-based drugs in the treatment of respiratory disorders, including both basic and clinical studies. Databases, including PubMed, Web of Knowledge, and Scopus, were searched until the end of August 2022 regarding the effect of nanoparticles on respiratory diseases. As a new tool, nanomedicine offered promising applications for the treatment of pulmonary diseases...
2023: Frontiers in Pharmacology
https://read.qxmd.com/read/37535431/pulmonary-delivery-of-specialized-pro-resolving-mediators-based-nanotherapeutics-attenuates-pulmonary-fibrosis-in-preclinical-animal-models
#14
JOURNAL ARTICLE
Jiulong Li, Yu Xiao, Yumo Zhang, Silu Li, Minzhi Zhao, Tian Xia, Huan Meng
Pulmonary fibrosis (PF) is a chronic lung disease characterized by excess extracellular matrix deposition and prolonged inflammation that fails to resolve and is druggable. Using resolvins and their precursors for inflammation resolution, we demonstrate a nano-enabled approach for accomplishing robust antifibrotic effects in bleomycin- or engineered nanomaterial-induced mouse and rat PF models. Targeting the lipid peroxidation-triggered NLRP3 inflammasome and NF-κB pathway in macrophages and the ROS-mediated TGF-β/Smad and S1P signaling in epithelial cells results in these potent protective effects at the ng/mL dosimetry...
August 3, 2023: ACS Nano
https://read.qxmd.com/read/37523222/magnetic-resonance-imaging-of-aerosol-deposition
#15
REVIEW
Richard B Thompson, Chantal Darquenne
Nuclear magnetic resonance imaging (MRI) uses non-ionizing radiation and offers a host of contrast mechanisms with the potential to quantify aerosol deposition. This chapter introduces the physics of MRI, its use in lung imaging, and more specifically, the methods that are used for the detection of regional distributions of inhaled particles. The most common implementation of MRI is based on imaging of hydrogen atoms (1 H) in water. The regional deposition of aerosol particles can be measured by the perturbation of the acquired 1 H signals via labeling of the aerosol with contrast agents...
July 31, 2023: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://read.qxmd.com/read/37458106/cardiopulmonary-impact-of-electronic-cigarettes-and-vaping-products-a-scientific-statement-from-the-american-heart-association
#16
REVIEW
Jason J Rose, Suchitra Krishnan-Sarin, Vernat J Exil, Naomi M Hamburg, Jessica L Fetterman, Fumito Ichinose, Miguel A Perez-Pinzon, Mary Rezk-Hanna, Eric Williamson
Vaping and electronic cigarette (e-cigarette) use have grown exponentially in the past decade, particularly among youth and young adults. Cigarette smoking is a risk factor for both cardiovascular and pulmonary disease. Because of their more limited ingredients and the absence of combustion, e-cigarettes and vaping products are often touted as safer alternative and potential tobacco-cessation products. The outbreak of e-cigarette or vaping product use-associated lung injury in the United States in 2019, which led to >2800 hospitalizations, highlighted the risks of e-cigarettes and vaping products...
August 22, 2023: Circulation
https://read.qxmd.com/read/37398980/hollow-polydopamine-nanocarrier-based-near-infrared-light-ph-responsive-drug-delivery-system-for-diffuse-alveolar-hemorrhage-treatment
#17
JOURNAL ARTICLE
Lingyan Zhang, Mifang Li, Yeying Wang, Yibiao Liu, Feiyuan Zhang, Zhihao Lin, Yuling Zhang, Mingliang Ma, Shouju Wang
Introduction: Diffuse alveolar hemorrhage (DAH) is a serious complication caused by systemic lupus erythematosus (SLE). Tissue damage and changes in immune response are all associated with excessive free radical production. Therefore, removing excess reactive oxygen species are considered a feasible scheme for diffuse alveolar hemorrhage treatment. Cyclophosphamide is often used as the main therapeutic drug in clinics. However, CTX carries a high risk of dose-increasing toxicity, treatment intolerance, and high recurrence rate...
2023: Frontiers in Chemistry
https://read.qxmd.com/read/37376143/designing-aerosol-therapies-based-on-the-integrated-evaluation-of-in-vitro-in-vivo-and-in-silico-data
#18
JOURNAL ARTICLE
Margaret Bourlon, Yu Feng, Lucila Garcia-Contreras
Despite the advantages of the pulmonary route of administration and inhalable dosage forms, other routes of administration and dosage forms are often considered first to treat lung diseases. This occurs, in part, due to the perceived limitations of inhaled therapies resulting from the improper design and interpretation of their in vitro and in vivo evaluation. The present study outlines the elements that should be considered in the design, performance, and interpretation of the results of the preclinical evaluation of novel inhaled therapies...
June 9, 2023: Pharmaceutics
https://read.qxmd.com/read/37262184/aerosol-particle-size-influences-the-infectious-dose-and-disease-severity-in-a-golden-syrian-hamster-model-of-inhalational-covid-19
#19
JOURNAL ARTICLE
Jeremy A Boydston, Jennifer Biryukov, John J Yeager, Heather A Zimmerman, Gregory Williams, Brian Green, Amy L Reese, Katie Beck, Jordan K Bohannon, David Miller, Denise Freeburger, Amanda Graham, Victoria Wahl, Michael C Hevey, Paul A Dabisch
Background: Significant evidence suggests that SARS-CoV-2 can be transmitted via respiratory aerosols, which are known to vary as a function of respiratory activity. Most animal models examine disease presentation following inhalation of small-particle aerosols similar to those generated during quiet breathing or speaking. However, despite evidence that particle size can influence dose-infectivity relationships and disease presentation for other microorganisms, no studies have examined the infectivity of SARS-CoV-2 contained in larger particle aerosols similar to those produced during coughing, singing, or talking...
June 1, 2023: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://read.qxmd.com/read/37241899/antitumor-effect-of-bleomycin-nanoaerosol-in-murine-carcinoma-model
#20
JOURNAL ARTICLE
Saida S Karshieva, Gulalek Babayeva, Vadim S Pokrovsky, Yuri M Shlyapnikov, Elena A Shlyapnikova, Anna E Bugrova, Alexey S Kononikhin, Evgeny N Nikolaev, Igor L Kanev
Bleomycin, which is widely used as an antitumor agent, possesses serious adverse effects such as pulmonary toxicity. Local nanoaerosol deposition for lung cancer treatment is a promising alternative to drug delivery to lung lesions. The aim of this work is to test the hypothesis that bleomycin nanoaerosol can be effectively used to treat multiple lung metastases. To obtain bleomycin nanoaerosol, an aerosol generator based on electrospray of a solution of a nonvolatile substance with gas-phase neutralization of charged aerosol particles was used...
May 18, 2023: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
keyword
keyword
52496
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.